DOCSLIB.ORG

COVID-19 Vaccine Weekly Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Vaccine Weekly Update Ramona Whittington From: Roxana Cruz Sent: Tuesday, February 23, 2021 10:02 PM To: [email protected]; [email protected]; Myrta Garcia; Lindsay Lanagan; catherine.threatt; [email protected]; Medical Directors; Dental Directors; [email protected]; [email protected] Cc: ClinicalTeam; Cassandra Caravello; Jana Eubank; Daniel Diaz; Shelby Tracy; Nancy Gilliam; Ramona Whittington Subject: COVID-19 Vaccine Weekly Update: Week 11 (02/22/2021) Attachments: COVIDVaccineAllocation-Week11_final.pdf; americanlungassociation_vaccineeducationtoolkit.pdf; ACP_Addressing Mistrust About COVID-19 Vaccines.pdf; COVIDVaccineAllocation-Week10.pdf Dear Fellow CMOs and Vaccine Coordinators, We hope you are well and that your communities have recovered since last week’s winter storm. As I am sure you know by now, COVID vaccine distribution was put on hold last week 2/15‐ 2/19 (Week 10) due to the inclement weather. Per the weekly DSHS Call today, the following updates were provided: • 100K of 1st dose vaccine not shipped/distributed • 300K of 2nd dose vaccine not shipped/distributed • 1 million vaccine doses will be distributed this week, to include last and this week’s allotments. • 600k 1st doses will go to 563 providers in 230 counties • Mass vaccination clinics this week: Dallas, Tarrant, Harris Counties COVID‐19 Vaccine Weekly Update: Week 11 (02/22/2021) During week 11, there were 61 health center sites that received allocations that total 18,550 doses this week. Vaccine Allocations for Week 11 (02/22/2021) attached w/orange highlighted health center sites. Vaccine Allocations for Week 10 (02/15/2022) although previously sent out, we have attached this list again for your reference. This brings total doses allocated to health centers: 117,525 vaccine doses to date. 266 Texas Health Center sites have been approved 218 Health Center sites have been approved and allocated vaccines 15 Health Center sites, which have been APPROVED by DSHS as registered COVID Vaccine Providers, but have not been allocated any vaccines to date. TACHC continues to advocate to DSHS and EVAP to obtain allocations for these sites. 6 health center sites have PENDING APPROVAL status as COVID Vaccine Providers, TACHC is working with DSHS to have these approved as quickly as possible. GOOD NEWS: Announcement on 2nd Dose‐ do not need to request 2nd dose through VAOS‐ 2nd dose will be automatically shipped (Moderna 28 days; Pfizer 4 weeks). ** Please note, if/when transferring Vaccines Allocations from Health Center Organization to another Organization, it is the responsibility of the health center site that received the 1st dose shipment and then transferred this to another organization/facility, to transfer 2nd dose shipment to the other organization/facility. FQHC Federal initiative to begin this week 1 As the White House announced on February 9, 2021, the Health Resources and Services Administration (HRSA) is working with the Centers for Disease Control and Prevention (CDC) to launch the first phase of a new Health Center COVID‐19 Vaccine Program. More than 1,300 HRSA‐funded health centers provide primary care services in underserved communities, serving almost 30 million people across the country. Two‐thirds of the population that these health centers serve are living at or below the federal poverty line, and 60 percent are racial and/or ethnic minorities. The goal of the Health Center COVID‐19 Vaccine Program is to provide a direct supply of COVID‐19 vaccines to health centers who serve the most vulnerable communities, in order to address health equity and reach those who have been hardest hit by the pandemic. This new program is being designed to complement—and not supplant—the COVID‐19 vaccine doses currently being distributed by states and jurisdictions. The program will be phased in as vaccine supply increases nationally and is being carried out in coordination with jurisdictions and health centers. The Health Center COVID‐19 Vaccine Program will initially include 250 health centers and up to one million doses. Over time, it will become available to all health centers and Health Center Program look‐alike organizations. More information on this program is available at http://www.hrsa.gov/coronavirus/health‐center‐program, including a list of the 250 health centers invited to be in the program’s initial phase. Participating Health Centers in Texas: The first list below names the initial 25 health centers that are participating in the program as of Monday, February 15. COMMUNITY ACTION CORPORATION OF SOUTH TEXAS ALICE TX UNITED MEDICAL CENTERS EAGLE PASS TX LEGACY COMMUNITY HEALTH SERVICES, INC. HOUSTON TX GATEWAY COMMUNITY HEALTH CENTER INC LAREDO TX BARRIO COMPREHENSIVE FAMILY HEALTH CARE CENTER, INC. SAN ANTONIO TX Invited Health Centers in Texas: The second list shows the additional health centers that HRSA invited to participate. TRAVIS COUNTY HEALTHCARE DISTRICT AUSTIN TX DALLAS COUNTY HOSPITAL DISTRICT DALLAS TX CENTRO SAN VICENTE EL PASO TX LONE STAR CIRCLE OF CARE GEORGETOWN TX HARRIS HEALTH SYSTEM HOUSTON TX EL CENTRO DEL BARRIO SAN ANTONIO TX HEART OF TEXAS COMMUNITY HEALTH CENTER, INC. WACO TX HRSA used a data‐driven approach to determine the initial health centers chosen for this program, including those that serve a large volume of one of the following disproportionately affected populations: • Individuals experiencing homelessness, • Migrant/seasonal agricultural workers, • Public housing residents, or • Patients with limited English proficiency. HRSA and CDC staff have coordinated with DSHS and also shared how information about vaccines allocated and administered through the ‘Health Center COVID‐19 Vaccine Program’ to support jurisdictional planning and management. HRSA has also worked in close coordination with TACHC to help determine health center willingness and readiness to participate. HRSA staff also conducted a formal readiness assessment with each health center to ensure their vaccine provider sites had the capacity to receive and administer additional vaccines from this new program. Additionally, health centers who agree to participate are required to: • Enroll in CDC’s COVID‐19 Vaccination Program and comply with all conditions in the COVID‐19 Vaccination Program Provider Agreement; • Complete HRSA’s Health Center COVID‐19 Vaccine Program Readiness Assessment to document and certify vaccine administration capacity; • Report required data, including the weekly HRSA Health Center COVID‐19 survey and addendum and any other state, local, and federal data reporting requirements; and 2 • Ensure timely administration of COVID‐19 vaccines provided through the program to established health center patients, as well as other individuals who present for such services (i.e. new patients) as capacity permits, while following priority guidelines established by the health center’s jurisdiction. The first 25 health centers and approximately 160 sites were able to start ordering vaccines as early as February 19, 2021. Vaccine Updates: “Delayed Second Dose versus Standard Regimen for Covid‐19 Vaccination” DOI: 10.1056/NEJMclde210198 UPDATED February 10, 2021 Interim Clinical Considerations for use of mRNA COVID‐19 Vaccines Currently Authorized in the United States Please note specifically: Appendix A Vaccine Administration Errors and Deviations (3/4 down page) Clarification on Contraindication and Precaution New recommendations for administration errors Guidance updates on quarantine and exposure MMWR 2/19/2021‐ First Month of COVID‐19 Vaccine Safety Monitoring Johnson & Johnson coronavirus vaccine could receive FDA approval as early as next week; however, DSHS indicated that there is not a large supply for this vaccine if/when approved. The allocations will be shipped with minimum quantity of 2400 vaccines. Johnson & Johnson Announces Single‐Shot Janssen COVID‐19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial (https://www.jnj.com/johnson‐johnson‐announces‐single‐shot‐ janssen‐covid‐19‐vaccine‐candidate‐met‐primary‐endpoints‐in‐interim‐analysis‐of‐its‐phase‐3‐ensemble‐trial J& J vaccine is an adenovirus vector‐based vaccine, developed by its subsidiary Janssen Pharmaceutical J&J’s vaccine was 85% overall effective in preventing severe disease and demonstrated complete protection against Covid‐19‐related hospitalization and death 28 days after vaccination. Novavax Covid‐19 vaccine [NVX‐CoV2373] Novavax 2‐dose vaccine showed 89.3% efficacy in a Phase III UK trial. Novavax is a recombinant nanoparticle of the SARS‐CoV‐2 spike protein with a saponin‐based adjuvant. Although efficacy rates are 66% for the J& J single‐dose vaccines and Novavax’s candidate showed a more potent efficacy of 89.3% with two doses, strategies to consider include consideration that potentially twice as many people can get vaccinated with J&J’s vaccine in the same time frame. Bloomberg’s COVID‐19 Vaccine Tracker: https://www.bloomberg.com/graphics/covid‐vaccine‐tracker‐global‐ distribution/ Therapeutics for COVID‐19: Therapeutics Mini‐Series: Equity and Underserved Populations Wednesday, February 24, 2021 scheduled for 11:00 AM ‐ 12:00 PM CST For Registration and Connection Information ‐ Please Click Here CDC Updates: Interim U.S. Guidance for Risk Assessment and Work Restrictions for Healthcare Personnel with Potential Exposure to SARS‐CoV‐2 As of February 16, 2021 CDC interim guidance was updated to: Clarified that work restriction of asymptomatic HCP with a higher‐risk exposure who have
Load more

Recommended publications
  • Coalition Communication: Healthcare
    Updated 1/15/2021 Coalition Communication: Healthcare COVID-19 UPDATES We need your help in sharing information about the COVID-19 vaccine. KEY STATS Vaccine.coronavirus.ohio.gov is an online resource for Ohioans to learn which providers received a COVID-19 vaccine allotment and how to contact them. Data as of 1/14/2021 Tentative dates to start vaccinating these Phase 1B populations are: • Jan. 19, 2021—Ohioans 80 years of age and older. PUBLIC HEALTH • Jan. 25, 2021—Ohioans 75 years of age and older; those with severe ADVISORY SYSTEM congenital or developmental disorders. • Feb. 1, 2021—Ohioans 70 years of age and older; employees of K-12 schools that wish to remain or return to in-person or hybrid learning. • Feb. 8, 2021—Ohioans 65 years of age and older. When a new age group begins, vaccinations may not be complete for the previous age group. It will take a number of weeks to distribute all of the vaccines given the limited doses available. If you are older than 65, please connect with an Area Agencies on Aging about questions or if you need transportation assistance. For more information, visit aginig.ohio.gov or call 1-866-243-5678. More information can be found at coronavirus.ohio.gov. 21-DAY TRENDS INDUSTRY INFORMATION Case Average 7,316 ■ The Ad Council and the COVID Collaborative have released a series of Death Average 73 videos, available in a YouTube playlist, feature an introduction from Dr. Anthony Fauci and include experts leading healthcare organizations. Hospitalization 293 Average ■ BlackDoctor.org’s Making It Plain: What Black America Needs to Know ICU Admission 29 About COVID-19 and Vaccines aired on January 7 and is now available on- Average demand on YouTube.
    [Show full text]
  • UMBC Alumnae Racing to Develop Coronavirus Vaccine
    Newsletter SPRING 2020 To our UMBC/Meyerhoff families: We hope you and your families are all doing well during this strange and stressful time of Covid- 19. Although the world has changed quickly with so many things shut down and many of us sheltering at home, we hope this newsletter will represent a ray of sunshine during a dark and difficult time. Please enjoy this positive representation of our student and alumni community. MPA Board UMBC Alumnae Racing to Develop Coronavirus Vaccine Kizzmekia Corbett ’08, M16, biological sciences, says it feels like she’s “living in a constant adrenaline rush.” Maybe that’s because she and her team at the Vaccine Research Center at the National Insti- tute of Allergy and Infectious Diseases have been working around the clock for weeks. They’re racing to develop a vaccine for the coronavirus faster than it can race across the globe. “To be living in this moment where I have the opportunity to work on something that has imminent global importance…it’s just a surre- al moment for me,” Corbett says. Despite it feeling surreal, the advances Corbett and her team are making are very real, and they’re setting records. “We are making better progress than I could have ever hoped for,” she says. After three months of studies in test tubes and in animals, the vaccine her team developed is about to enter a phase I clinical trial, a crucial hur- dle on the way to FDA approval. Read the complete article about Kizzmekia and her team’s efforts to develop a Covid-19 vaccine in the latest UMBC magazine at https:// Kizzmekia Corbett, NIH magazine.umbc.edu/umbc-alumnae-racing-to-develop- coronavirus-vaccine/.
    [Show full text]
  • Covid-19 Vaccination Disparities and Hesitancy
    COVID-19 VACCINATION DISPARITIES AND HESITANCY + Stanley Thompson, MD, MHA, FACEP + David Hogan, DO, MPH, FACEP + Khadeja Haye, MD, MBA, FACOG teamhealth.com COVID-19 VACCINATION DISPARITIES AND HESITANCY Numerous studies have shown that the COVID-19 pandemic has disproportionately affected people of color in the United States. Black, Hispanic or Latinx, and Native American people are approximately four times more likely to be hospitalized and nearly three times more likely to die of COVID-19 than their majority counterparts. There are numerous reasons for these disparities, many of which are the same as other findings of disparity in other disease states (i.e. the social determinants of medicine). We know that vaccination is the key to preventing COVID-19 in all people. Vaccinated People – What We Know America’s vaccination effort is among the best in the world. However, where race is known, people of color are getting vaccinated at lower rates than white Americans. The Kaiser Family Foundation analysis reveals a significant disparity where race is known (about 54%) for those who have received at least one dose of vaccine as of April 13, 2021. It shows the racial/ethnic breakdown as White Americans 65%, Hispanic or Latinx 11%, Black 9%, Asian 5%, Indigenous American or Alaskan 2%, Native Hawaiian <1%, and Multiple race 9%. A YouGov poll further supports and illustrates this point as well. Among White adults polled, 26% have gotten the vaccine, compared to 17% of Black adults and 11% of Hispanic adults. Access to Vaccines A big part of what is occurring is disparate access to vaccination.
    [Show full text]
  • Dân Chúa on Line Số 67 - Tháng 1.2021 Nguyệt San Công Giáo Trong Số Này Katholische on Line
    Dân Chúa on line số 67 - tháng 1.2021 Nguyệt San Công Giáo Trong Số Này Katholische on line . Lá Thư Chủ Nhiệm. Monthly Catholic on line . Lịch Phụng vụ tháng Một 2021. Email: [email protected] . Năm Mục vụ Giới Trẻ 2021. Herausgeber: Franz Xaver e.V. Ghen và ghét. Dân Chúa Katholische on line . Khi Nào Trẻ Em DÂN CHÚA ÂU CHÂU Có Thể Chích Ngừa Covid-19? Chủ nhiệm: Lm Stêphanô Bùi Thượng Lưu . Những Ai Đã Góp Phần Sáng Chế Phụ tá chủ nhiệm: Lm Paul Đào Văn Thạnh Thuốc Ngừa Covid-19?. Thư ký : Sr. Anne Marie Nguyễn Thị Hường . Khát vọng Hòa Bình. Chủ biên thần học : Lm Vincent Lê Phú Hải omi . Đánh giá đời sống thiêng liêng Chủ biên văn hóa: Sh Bonaventure Trần Công Lao qua 4 điểm cốt yếu. hình bìa : Trần Anh Dũng omi. Một năm đặc biệt để làm chứng DÂN CHÚA ÚC CHÂU cho tình yêu gia đình. 715 Sydney Rd. Brunswick, Victoria 3056 . Loài Người Đã Được Tạo Dựng Tel.: (03) 9386-7455 / Fax: (03) 9386-3326 Hay Do Tiến Hóa?. Chủ nhiệm: Lm. Nguyễn Hữu Quảng SDB . Nguồn gốc vũ trụ theo Thánh Kinh Chủ bút: Rev. James Võ Thanh Xuân và khoa học. Phụ tá Chủ bút: Trần Vũ Trụ . Thiên Chúa Sáng Tạo Vũ Trụ Tổng Thư Ký: Sr. Nguyễn Thùy Linh, FMA Và Con Người. Ban kỹ thuật: Hiệp Hải . Trái đất có thể khóc không?. NHÀ KHẢO CỔ NGƯỜI ANH TIN RẰNG Mục đích & Tôn CHỈ Dân Chúa ÔNG ĐÃ TÌM THẤY NGÔI NHÀ Mục đích: Góp phần vào việc phục vụ tập thể Công THỜI THƠ ẤU CỦA CHÚA GIÊSU Giáo Việt Nam và đồng bào để cùng thăng tiến toàn .
    [Show full text]
  • What Contributes to COVID-19 Vaccine Hesitancy in Black Communities, and How Can It Be Addressed?
    Research Report C O R P O R A T I O N LAURA M. BOGART, LU DONG, PRIYA GANDHI, SAMANTHA RYAN, TERRY L. SMITH, DAVID J. KLEIN, LUCKIE ALEXANDER FULLER, BISOLA O. OJIKUTU What Contributes to COVID-19 Vaccine Hesitancy in Black Communities, and How Can It Be Addressed? ecent polls show that Black Americans are less willing than Americans of other races or ethnicities to be vaccinated for COVID-19, even after the November 2020 announcements by pharmaceutical companies Pfizer and BioNTech and Moderna about their vaccines’ R 1 high efficacy. For example, responses to a November 2020 poll of an online survey panel found that 42 percent of Black Americans, versus 63 percent of Hispanic or Latinx Americans and 61 percent of White Americans, said that they would definitely or probably get vaccinated.2 A December 2020 nationally representative telephone poll found that 35 percent of Black adults said KEY FINDINGS that they would definitely not or Q A survey of a nationally representative sample of 207 Black Ameri- probably not get vaccinated3—and cans conducted in late 2020 found high levels of vaccine hesitancy about half of those who did not and mistrust of COVID-19 vaccines in the overall sample, as well as want to get vaccinated cited mistrust among health care workers in particular. of vaccines as well as worry about Q Those who expressed vaccine hesitancy also showed high levels getting COVID-19 from the vaccine of overall mistrust, concerns about potential harm and side effects, as main reasons. Evidence thus and lack of confidence in vaccine effectiveness and safety.
    [Show full text]
  • Newsletter Spring 2021
    A Year Like No Other - the 2020 UGSP Newsletter Written and Assembled by UGSP Newsletter Committee Charlesice Grable-Hawkins (Chair), Nyree Riley, Makheni Jean-Pierre “Each time new experiments are observed to agree with the predictions the theory survives, and our confidence in it is increased; but if ever a new observation is found to disagree, we have to abandon or modify the theory.” - Dr. Stephen Hawking From the global push to develop a vaccine, institutional restructuring, and changing schedules to the massive transition into a virtual environment, the year of 2020 was nothing like anyone could have planned for. This near universal experience has led many to reassess the working model of their everyday lives, to reflect and experiment with how they approach their wellness and their connections with others, and to think critically about moving forward. The Undergraduate Scholarship Program, under the direction of Dr. Darryl Murray, continues to support students who are from disadvantaged backgrounds and who are passionate about advancing biomedical, behavioral, and social science fields for the improvement of human health. This newsletter will highlight some of the ways in which current UGSP scholars have adapted to the challenges of 2020, provide insight into the perspective of both a mentee and mentor, as well as how UGSP alumni Dr. Kizzmekia Corbett has contributed to the development of the Moderna SARS-CoV-2 vaccine. Table of Contents Dr. Kizzmekia Corbett – a Powerful Voice in Science During COVID-19 ....................................................... 2 Current Scholars ............................................................................................................................................ 3 UGSP Alum and Mentor Reflections ............................................................................................................. 4 Dr. Darryl Murray’s go-to wellness activity over this past year has been walking his family’s new rescue dog Pepper! Dr.
    [Show full text]
  • March 11, 2021
    Sector Email 3.11.2021 Subject header: Updates on COVID-19 from Public Health - Seattle & King County (PHSKC) Schools Dear school partners, March is Women’s History Month and this year we are grateful to some of the women who are making history by changing the course of the COVID-19 pandemic. Have you learned about Kizzmekia Corbett, an African American Immunologist who co-led the development of the Moderna COVID-19 vaccine. This month, we celebrate Dr. Corbett and thousands of her colleagues in healthcare, research and public health as women who are making history. Reminder: please review the King County Schools COVID-19 Response Toolkit, related resources, and training videos. ---------- This week’s Public Health—Seattle & King County (PHSKC) Schools and Child Care Task Force sector email includes the following topics: 1. Key indicators of COVID-19 activity 2. Vaccine Updates a. Educators, school staff and child care workers now eligible for COVID-19 vaccine b. How school and child care staff can access vaccines c. Getting Vaccinated Resources d. Signs and Symptoms Following Vaccination 3. COVID Community Vaccination Event Planning Workbooks 4. Special Enrollment for Washington Health Care 5. Updated Mask Posters 6. Events a. Public Health’s upcoming trainings and community discussions on COVID-19 b. COVID-19 Vaccination Webinar and Q&A c. COVID-19 Vaccine Distribution Webinar and Q&A d. Oromo Session – COVID-19 and Vaccinations e. Somali Session – COVID-19 and Vaccinations 7. Updated Guidance from the CDC – When You’ve Been Fully Vaccinated 8. School and District Town Hall Meetings 9.
    [Show full text]
  • Kizzmekia S. Corbett
    KIZZMEKIA S. CORBETT, PHD Senior Research Fellow National Institutes of Health | National Institute of Allergy and Infectious Diseases | Vaccine Research Center 40 Convent Drive, Building 40 - Room 2608, Bethesda MD 20892 [email protected] | phone: 301.761.7610 | fax: 301.480.2771 EDUCATION Doctor of Philosophy in Microbiology and Immunology 2014 University of North Carolina at Chapel Hill (UNC) Director’s Scholar Bachelor of Science in Biological Sciences | Secondary Major in Sociology 2008 University of Maryland – Baltimore County (UMBC) Robert and Jane Meyerhoff Scholar RESEARCH EXPERIENCE Research Fellow 10/14 - present National Institutes of Health | Vaccine Research Center | PI: Barney S. Graham, MD PhD Research Interest: mechanisms of viral immunity to inform influenza and coronavirus vaccine development Graduate Research Assistant 08/09 – 10/14 University of North Carolina at Chapel Hill | Microbiology and Immunology | PI: Aravinda de Silva, MPH PhD Research Interest: human antibody responses to dengue virus infection Visiting Scholar 04/14 – 05/14 Genetech Research Institute | PI: Aruna Dharshan de Silva, PhD Research Interest: immunological relevance of dengue virion maturation Postbaccalaureate Research Fellow 05/08 – 08/09 National Institutes of Health | Vaccine Research Center | PI: Barney S. Graham, MD PhD Research Interest: novel vaccine platform design for respiratory syncytial virus antigens NIH Undergraduate Scholarship Program Summer Intern 06/07 – 08/07 National Institutes of Health | Vaccine Research Center
    [Show full text]
  • That Record-Breaking Sprint to Create a COVID-19 Vaccine The
    NATIONAL INSTITUTES OF HEALTH • OFFICE OF THE DIRECTOR | VOLUME 29 ISSUE 5 • SEPTEMBER-OCTOBER 2021 That Record-breaking The Intersection of Man and Machine Sprint to Create a Bionics Gives New Hope to Those Living With Physical Disabilities COVID-19 Vaccine BY MICHAEL TABASKO, OD BY MELISSA GLIM At the end of 2019, most people were looking forward to an exciting 2020, a new decade starting with those magic numbers, 20-20, that denote a sharpness of vision. There would be the Summer Olympics in Japan and the U.S. presidential election. Meanwhile, intramural scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC) were designing vaccines for several coronaviruses using a promising, new platform based on messenger RNA (mRNA). Everything changed on a Saturday morning in early January. Chinese scientists CREDIT: TH0MAS BULEA (LEFT); NIH CLINCAL CENTER (RICHT) had isolated a new coronavirus that was (Left) The NIH pediatric exoskeleton for children with cerebral palsy and other movement disorders uses custom actuators causing a serious epidemic in China’s Wuhan from Agilik developed as part of a cooperative research and development agreement with NIH, along with embedded sensors and microcontrollers, to provide overground gait training while worn. (Right) Alexander Theodorakos, a participant province and released its genetic sequence to in a research protocol at the NIH Clinical Center that is evaluating the new pediatric exoskeleton, and Thomas Bulea, the the scientific community around the world. study’s principal investigator, discuss how the device changes the way the legs move when walking. Barney Graham, director of the VRC’s Viral Pathogenesis Laboratory (VPL), and If popular culture is any indication, the notion that bionic technology will VRC research fellow Kizzmekia Corbett someday redefine the boundaries of human function has long held our collective dropped everything and began using this fascination.
    [Show full text]
  • People in the News
    Volume XXX, Number XLII December 24, 2020 - January 6, 2021 Seeking to end the ‘Slavery Loophole’ - See Page 3 Black nurse takes the first vaccine Visit us online at www.northdallasgazette.com - See Page 4 COVID-19 won’t stop toy giveaway - See Page 5 Advocating for education in Washington, DC - See Page 6 Black women fill top posts under Biden - See Page 8 Cowboys stun the 49ers - See Page 9 A look back at the best films of 2020 - See Page 11 Sister Tarpley: New Year, New Attitude Background: OC Gonzalez / Unsplash, Pride: Republic Country Club / Wikimedia, Harris: Official Portrait, OC Gonzalez / Unsplash, Pride: Republic Country Club Wikimedia, Background: - See Page 15 Inside... See Page 2 People In The News ... People in the News ........................................ 2 Op/Ed ............................................................ 3 Health ............................................................ 4 Community .................................................... 5 Education ...................................................... 6 Features ........................................................ 8 Dallas Cowboys ............................................. 9 NDG Bookshelf ............................................ 11 Dr. Kizzmekia Corbett Gen. Lloyd Austin Rashida Jones Marketplace ................................................ 12 Career / Notices .......................................... 13 NDG Quote of the Week: ““The future belongs to those who prepare for it today.” Church Directory ...................................
    [Show full text]
  • February 2021
    Teacher Enrichment Program February 2021 Perspectives Science Virtual Bite of Science Rebuilding trust brick by brick Spring & Summer Events Calendar Dr. Kizzy Corbett, NIH lead for Moderna Vaccine, in an interview with Dr. Sanjay Gupta, CNN Chief Medical Date Virtual Event Target Area Correspondent February 25 Shenandoah & Technology Western VA COVID-19 warnings were on Twitter March 4 Northern California "Our study adds on to the existing evidence that social media can be a useful tool of epidemiological March 11 Florida surveillance." - Massimo Riccaboni, IMT School March 18 Pennsylvania Social media big data predicts contagion diffusion Information Discovery and Delivery March 25 Coastal & Eastern VA April 8 Texas Engineering Better face masks through origami April 15 Southern California “From basic pleats to complex interlocking folds, April 22 Maryland origami could deliver better fitting, more comfortable, and more stylish face coverings.” - National Geographic May 6 West Virginia May 13 Indiana Mathematics DNA and true random number generation Exploiting the stochastic nature of chemistry through You are invited to sign up for any session of interest, DNA synthesis as a model for encryption and regardless of target area. Find more information about decryption of sensitive information. - Nature each event on the TEP Homepage. Thank you! Timeless STEM The mission of Project Drawdown is to promote global awareness of community- A big thank you to based conservation. Project Drawdown Claude Moore Charitable Foundation, shares information about environmental one of the sponsors of TEP’s impact sectors such as agriculture, Virtual Bite of Science events. transportation, health & education, and Learn more here. more. Visit Project Drawdown here.
    [Show full text]
  • Croi 2021 Program Committee
    General Information CONTENTS WELCOME . 2 General Information General Information OVERVIEW . 2 CONTINUING MEDICAL EDUCATION . 3 CONFERENCE SUPPORT . 4 VIRTUAL PLATFORM . 5 ON-DEMAND CONTENT AND WEBCASTS . 5 CONFERENCE SCHEDULE AT A GLANCE . 6 PRECONFERENCE SESSIONS . 9 LIVE PLENARY, ORAL, AND INTERACTIVE SESSIONS, AND ON-DEMAND SYMPOSIA BY DAY . 11 SCIENCE SPOTLIGHTS™ . 47 SCIENCE SPOTLIGHT™ SESSIONS BY CATEGORY . 109 CROI FOUNDATION . 112 IAS–USA . 112 CROI 2021 PROGRAM COMMITTEE . 113 Scientific Program Committee . 113 Community Liaison Subcommittee . 113 Former Members . 113 EXTERNAL REVIEWERS . .114 SCHOLARSHIP AWARDEES . 114 AFFILIATED OR PROXIMATE ACTIVITIES . 114 EMBARGO POLICIES AND SOCIAL MEDIA . 115 CONFERENCE ETIQUETTE . 115 ABSTRACT PROCESS Scientific Categories . 116 Abstract Content . 117 Presenter Responsibilities . 117 Abstract Review Process . 117 Statistics for Abstracts . 117 Abstracts Related to SARS-CoV-2 and Special Study Populations . 117. INDEX OF SPECIAL STUDY POPULATIONS . 118 INDEX OF PRESENTING AUTHORS . .122 . Version 9 .0 | Last Update on March 8, 2021 Printed in the United States of America . © Copyright 2021 CROI Foundation/IAS–USA . All rights reserved . ISBN #978-1-7320053-4-1 vCROI 2021 1 General Information WELCOME TO vCROI 2021 Welcome to vCROI 2021! The COVID-19 pandemic has changed the world for all of us in so many ways . Over the past year, we have had to put some of our HIV research on hold, learned to do our research in different ways using different tools, to communicate with each other in virtual formats, and to apply the many lessons in HIV research, care, and community advocacy to addressing the COVID-19 pandemic . Scientists and community stakeholders who have long been engaged in the endeavor to end the epidemic of HIV have pivoted to support and inform the unprecedented progress made in battle against SARS-CoV-2 .
    [Show full text]